Medicure, Inc. (NASDAQ:MCUJF) | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
Medicure, Inc.

BRIEF

published on 11/18/2024 at 23:05, 2 days 15 hours ago

Medicure to Present Q3 2024 Financial Results Amid Board Changes

Financial Results Conference Call Q3 2024 Board Resignation Medicure
PRESS RELEASE

published on 11/18/2024 at 23:00, 2 days 15 hours ago

Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member
Medicure Inc. announces 2024 Q3 Financial Results conference call on November 26, 2024. Board member resigns. Company specializes in pharmaceuticals & healthcare products

Conference Call Pharmaceuticals Medicure Inc. Healthcare Products 2024 Q3 Financial Results
BRIEF

published on 10/25/2024 at 00:05, 27 days 14 hours ago

Medicure Reaches Settlement in Product Development and Supply Contract

Pharmaceuticals Product Development Healthcare Products Medicure Settlement
PRESS RELEASE

published on 10/25/2024 at 00:00, 27 days 14 hours ago

Medicure Announces Positive Settlement of Product Development and Supply Contracts
Medicure Inc. settles a product development and supply contract with a third party, receiving €1.5 million. Details remain confidential. Company focuses on pharmaceuticals and healthcare products in the U.S. market

Pharmaceuticals Medicure Inc. Product Development Healthcare Products Supply Contract
BRIEF

published on 08/14/2024 at 23:35, 3 months 6 days ago

Medicure Completes Acquisition of Intellectual Property from CanAm Bioresearch

Intellectual Property CanAm Bioresearch Medicure Acquisition Therapeutic Development Pharmaceutical Assets
PRESS RELEASE

published on 08/14/2024 at 23:30, 3 months 6 days ago

Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
Medicure Inc. acquires intellectual property assets of CanAm Bioresearch Inc. related to new chemical entities for therapeutic use. Agreement terms and related party transaction details provided

Medicure Inc. New Chemical Entities Therapeutic Use CanAm Bioresearch Inc. Intellectual Property Assets
BRIEF

published on 08/14/2024 at 23:05, 3 months 6 days ago

Medicure Reports Financial Results for Quarter Ended June 30, 2024

Financial Results Marley Drug Medicure AGGRASTAT ZYPITAMAG
PRESS RELEASE

published on 08/14/2024 at 23:00, 3 months 6 days ago

Medicure Reports Financial Results for Quarter Ended June 30, 2024
Medicure Inc. reports Q2 2024 financial results: net revenue down, EBITDA negative, net loss recorded. AGGRASTAT and ZYPITAMAG sales impacted. Analyst call on Aug 15, 2024

Financial Results EBITDA Medicure Inc. Net Loss Q2 2024
BRIEF

published on 06/24/2024 at 23:05, 4 months 26 days ago

Medicure Announces Acquisition Agreement with CanAm Bioresearch Inc.

Pharmaceuticals Intellectual Property Asset Purchase Medicure CanAm Bioresearch
PRESS RELEASE

published on 06/24/2024 at 23:00, 4 months 26 days ago

Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Medicure Inc. announces asset purchase agreement with CanAm Bioresearch for acquisition of patent and intellectual property related to new chemical entities for therapeutic use

Medicure Inc. Asset Purchase Agreement CanAm Bioresearch New Chemical Entities Therapeutic Use

Accesswire

Published on 11/21/2024 at 14:00, 13 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 13 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 13 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 13 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 43 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 13 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 58 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 38 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 58 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 7 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 15 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 53 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 28 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 28 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE